Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN424 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs CVN-424 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors Cerevance
- 01 Apr 2022 Results published in the Journal of Pharmacology and Experimental Therapeutics
- 30 Apr 2019 Results pressented in a Cerevance Media Release.
- 30 Apr 2019 Status changed from active, no longer recruiting to completed, according to a Cerevance media release.